14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Tue, 25 Jun 2024

Trading levels for SCYX

Fibonacci Support & Resistance Levels

Level Price
R3 2.08 6.84%
R2 2.01 2.92%
R1 1.96 0.499%
Price 1.95
S1 1.81 -7.34%
S2 1.76 -9.76%
S3 1.68 -13.68%

Accumulated Volume Support & Resistance Levels

Level Price
R3 2.41 23.59%
R2 2.24 14.87%
R1 2.04 4.62%
Price 1.95
S1 1.82 -6.67%
S2 1.80 -7.69%
S3 1.47 -24.62%

SCYX Predictions History

3 years ago
sander7100 yo bro predicted that SCYX for 2020-09-11 is going $6.22 (20.54%)

3 years ago
JS predicted that SCYX for 2020-09-11 is going $5.33 (3.29%)

3 years ago
iHustle84 predicted that SCYX for 2020-09-11 is going $5.89 (14.15%)

3 years ago
sander7100 yo bro predicted that SCYX for 2020-09-08 is going $4.86 (-2.99%)

3 years ago
iHustle84 predicted that SCYX for 2020-09-08 is going $4.00 (-19.03%)

3 years ago
JS predicted that SCYX for 2020-09-08 is going $4.86 (-1.62%)

3 years ago
DeMichael Franklin predicted that SCYX for 2020-09-08 is going $6.40 (29.55%)

Rank:

4 years ago
Alan predicted that SCYX for 2019-08-12 is going $1.02 (-89.80%)

4 years ago
JS predicted that SCYX for 2019-07-22 is going $1.24 (-89.92%)

4 years ago
CoffeeNtrees predicted that SCYX for 2019-07-22 is going $1.29 (-89.51%)

Rank:
Click to get the best stock tips daily for free!

About SCYNEXIS

SCYNEXIS SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refrac... SCYX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT